Scilex Holding Company Presented Oral and Poster Presentations on Elyxyb at the 2023 Annual Brain Week Conference Held in Las Vegas, NV
PALO ALTO, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex”…
News
Scilex Holding Company Presented Oral and Poster Presentations on Elyxyb at the 2023 Annual Brain Week Conference Held in Las Vegas, NV
PALO ALTO, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex”…
Scilex Holding Company Presented Oral and Poster Presentations on ZTlido (lidocaine topical system) at the 2023 Annual PAINWeek Conference Held in Las Vegas, NV
PALO ALTO, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex”…
Scilex Holding Company Presented Oral and Poster Presentations on ZTlido (lidocaine topical system) at the 2023 Annual PAINWeek Conference Held in Las Vegas, NV
PALO ALTO, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex”…
In Recognition of Suicide Prevention Month, NeuroStar Voices Portal Amplifies Stories of Real People Beating Depression
Portal provides resources to raise awareness around mental health and suicide prevention MALVERN, Pa., Sept….
In Recognition of Suicide Prevention Month, NeuroStar Voices Portal Amplifies Stories of Real People Beating Depression
Portal provides resources to raise awareness around mental health and suicide prevention MALVERN, Pa., Sept….
Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes
JERUSALEM, Sept. 12, 2023 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX, “Entera”) and OPKO…
Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes
JERUSALEM, Sept. 12, 2023 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX, “Entera”) and OPKO…
GSAC Engineering Acquires Key Intellectual Property and Assets from Duos Technologies Group
GelStat’s Subsidiary, GSAC Engineering, Launches Intelligent Correctional Facilities Automation Systems (iCAS) in the Industrial Security…
GSAC Engineering Acquires Key Intellectual Property and Assets from Duos Technologies Group
GelStat’s Subsidiary, GSAC Engineering, Launches Intelligent Correctional Facilities Automation Systems (iCAS) in the Industrial Security…
Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042
REDWOOD CITY, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) — Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a…
Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042
REDWOOD CITY, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) — Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a…
IO Biotech Announces New Data Related to its IO102-IO103 Therapeutic Cancer Vaccine Presented Today at the IASLC 2023 World Conference on Lung Cancer
Encouraging interim data support the potential of IO102-IO103 in combination with pembrolizumab as first-line treatment…
IO Biotech Announces New Data Related to its IO102-IO103 Therapeutic Cancer Vaccine Presented Today at the IASLC 2023 World Conference on Lung Cancer
Encouraging interim data support the potential of IO102-IO103 in combination with pembrolizumab as first-line treatment…
A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC
• Data presented at the 2023 World Conference on Lung Cancer hosted by the International…
A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC
• Data presented at the 2023 World Conference on Lung Cancer hosted by the International…
Spinogenix Awarded $3 Million NIH Grant to Support Continued Development of SPG302, the First Synaptic Regenerative Therapeutic for Alzheimer’s Disease
Treatment Could Help Restore Brain Functions Lost in Many Neurogenerative Disorders SAN DIEGO, Sept. 12,…
Spinogenix Awarded $3 Million NIH Grant to Support Continued Development of SPG302, the First Synaptic Regenerative Therapeutic for Alzheimer’s Disease
Treatment Could Help Restore Brain Functions Lost in Many Neurogenerative Disorders SAN DIEGO, Sept. 12,…
Avalyn Pharma Presents Data Showing Favorable Tolerability and Potential of AP01 to Preserve Forced Vital Capacity in Adults with Pulmonary Fibrosis
Seattle, Sept. 12, 2023 (GLOBE NEWSWIRE) — Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused…
Avalyn Pharma Presents Data Showing Favorable Tolerability and Potential of AP01 to Preserve Forced Vital Capacity in Adults with Pulmonary Fibrosis
Seattle, Sept. 12, 2023 (GLOBE NEWSWIRE) — Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused…